Pharvaris N.V. Ordinary Shares
PHVSPharvaris N.V. is a biopharmaceutical company focused on developing therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by severe swelling episodes. The company's approach involves targeting the kallikrein-kinin system to develop innovative treatments that address the underlying causes of HAE. Headquartered in the Netherlands, Pharvaris aims to improve the quality of life for patients through its pipeline of novel oral and injectable therapies.
Company News
Bain Capital Life Sciences Investors sold 122,106 shares of Pharvaris N.V. during Q3 2025, reducing its position value by $21.23 million while maintaining a significant stake. The sale appears to be profit-taking rather than a negative sentiment shift.
Pharvaris, a biopharmaceutical company, has priced a public offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 shares, expecting to raise approximately $175 million.
Pharvaris presented data at the EAACI Congress 2025 supporting the potential of its oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks.
ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on Friday, June 28, 2024, at 15:00 CES...
ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, recently presented data highlighting the unique pharmacological and clinical properties of deucrictibant for the ...
